LEAD DISCOVERY SIENA

Business Type:

Srl

Start-up:

Company Size:

Micro

Website: http://leaddiscoverysiena.it/
info@leaddiscoverysiena.it
+39 0577 234256

VAT number:

01333250528

Registered office address:

Strada del Petriccio e Belriguardo 35 - 53100 - Siena-SI

Overview:

Lead Discovery Siena (LDS) is a startup providing tools and expertise to develop drug discovery programs, offering pharmaceutical services for industry and academia. It has a diversified pipeline of in licensed and proprietary products for oncology and infections therapeutic areas, including rare diseases. LDS focus is to foster the design and development of early drug discovery campaigns up to pre-clinical phases, exploiting its expertise in pharmaco-kinetics and -dynamics, solubility and permeability issues, toxicity and side effects, computational chemistry, custom synthesis, ADME tests. LDS offers also services as integrated medicinal chemistry services, a wide range of biological services, specific expertise in anticancer agent bioconjugation with antibodies. LDS actively participates to national and international projects, with a special attention to local synergies at industrial and academic level within the life science area.

Sectors :

Pharma/Biopharma	Formulation & drug delivery
Drugs by chemical synthesis
	Related activities and services	Research & Development
		Screening services, drug discovery
		Custom synthesis
	Analytical Services	ADME & toxilogical analysis
		Assays, analytical methods
		Biochemical analysis
		Microbiological analysis
		Physical-chemical characterization (UV,FLU, IR, Chrom, MS, NMR)
	CRO	Biologic assay development
		Custom Research Services
		Pre-clinical trials

Activity type:

Design & prototyping

Research & development

Services, consulting

Founding Year:

2012

Country already served:

EUROPE

Country of interest to be served:

AMERICA

ASIA

Products/Services

LDS Products

LDS has identified and developed novel compound families as new potential drugs for the treatment of cancers and bacterial infections. LDS owns the IP of these compound families and is looking for suitable opportunities to combine experience and resources with other organisations where specific projects may benefit in the form either of collaborations at various phases during the life of a program or through out-licensing of specific small molecules or classes.
- Oncology: LDS has developed a wide expertise on Src Family Kinase inhibitors as therapeutic intervention against a number of cancers. In vitro and in vivo studies have been conducted to advance most promising compounds, including PK, tolerability and efficacy in animal models. Current lead compound shows a clear efficacy in intracranial model of glioblastoma multiforme (GBM) in mice. In vivo PK studies confirmed the ability of the compound to cross the BBB.
- Antibacterial: the emergence of multi-drug, extremely-drug, or even pan-drug resistant bacteria have revealed that therapeutic options in this area are strongly limited. LDS is developing a library of compounds active against various bacterial strains including clinically Gram-negative pathogens. Moreover, LDS is involved in microbiota-focused projects (collaborations) to prevent antibiotic-associated disorders (AAD, IBS, C. difficile infections) which has led to 4 patent applications.
Services

LDS clients take advantage of our knowledge and competences to expedite their drug discovery programmes.

Services can be accessed as standalone projects or may be integrated as a part of a medicinal chemistry optimization programme to build customized solutions to meet drug discovery needs, from hit identification and follow-up, to lead optimization and back-up identification. Competencies include dealing with pharmaco-kinetics and -dynamics, solubility and permeability issues, toxicity and side effects.
- Custom synthesis: design and synthesis of on demand compound libraries or specific compounds from mg to gr scale.
- Computational Chemistry: computational models development (docking, molecular modeling, molecular dynamics, virtual screening, physico-chemical properties prediction, SAR and QSAR studies, etc) aimed at the rational design of novel compounds.
- ADME/PK: physico-chemical profiling (solubility, PAMPA permeability, Caco-2, metabolic stability. cytochrome inhibition), in vivo pharmacokinetic studies through main administration routes
- Protein production and purification
- Biological assay development and validation
- Target-based and whole-cell HTS
- Compound Profiling
- Biological products optimization (therapeutic proteins) and protein engineering
- Antibody Drug Conjugates (ADC): development of conjugation techniques with custom antibodies; development of attaching mode of custom toxins to antibodies; development of proprietary antibodies bioconjugated with innovative mode of action

Products/Services under development

Number of patents:

Brochure:

LDS Brochure.pdf

Looking for services, facilities , collaborations for a project in Life Sciences?

The cluster network provides a large panel of services and products for the growth of life sciences in Tuscany.

Here you can find an updated list of the facilties and equipments that the Cluster network makes available for the development of business projects and research activities.

The updated map with all members of the Cluster. Here you can find contacts of companies, research groups and organisations connected to the Tuscany cluster.

The Cluster Network